No­var­tis gets the green light to start mar­ket­ing its next prospec­tive block­buster. And they're charg­ing a pre­mi­um for ...

5 years ago
R&D
FDA+

Ron Evans steals a trick from I/O, and points the way to a trans­for­ma­tion­al di­a­betes ther­a­py

5 years ago
Discovery

Watch out Bris­tol My­ers, Mer­ck is right on your heels with more pos­i­tive Keytru­da da­ta to take to the FDA

5 years ago
R&D

Eli Lil­ly part­ner Ab­Cellera ac­quires bis­pe­cif­ic plat­form; Te­va faces more law­suits, this time over opi­oid mar­ket­ing

5 years ago
News Briefing

Is Take­da’s post-Shire sell-off ap­proach­ing its fi­nal days?

5 years ago
Deals

Sev­en PD-(L)1 play­ers could be vy­ing for a place on Chi­na's drug re­im­burse­ment list. How far will they go?

5 years ago
China
Pharma

Bris­tol My­ers joins the lab rush in Cam­bridge with plans to con­sol­i­date R&D ops in a biotech cam­pus now un­der ...

5 years ago
Pharma

Two more biotechs lever­age up­sized of­fer­ings in IPO boom as Har­bour pitch­es a raise in Hong Kong

5 years ago
Financing

Covid-19 roundup: Pfiz­er/BioN­Tech spell out PhI­II pri­or­i­ty; Le­gal ex­perts urge FDA to re­frain from vac­cine EUAs

5 years ago
Coronavirus

Alzheon re­turns, with a $47M NIH grant and one last shot at a piv­otal PhI­II Alzheimer’s suc­cess

5 years ago
Financing
R&D

Re­gen­eron flash­es ‘great ad­vance' in the NE­JM for that oth­er cho­les­terol drug sit­ting at the FDA

5 years ago
R&D

ROME founder Rosana Kapeller re­cruits a CSO from the se­nior ranks of a ma­jor league R&D team

5 years ago
People

Turn­ing Point touts pos­i­tive piv­otal NSCLC da­ta, hints at even faster OK — but can it beat Pfiz­er and Roche?

5 years ago
R&D

Bushu plans $100 mil­lion ex­pan­sion for phar­ma­ceu­ti­cal in­spec­tion fa­cil­i­ty; RUC­DR breaks away from Rut­gers Uni­ver­si­ty, ...

5 years ago
News Briefing

Opi­oids, price-fix­ing and now kick­backs. Pros­e­cu­tors add an­oth­er ‘en­rich­ing’ scheme to the claims against Te­va

5 years ago
Pharma

Fed­er­al judge de­nies Mar­tin Shkre­li all but one mo­tion to dis­miss mo­nop­oly claims in the FTC's Dara­prim law­suit

5 years ago
People
Pharma

In an­oth­er shock­er, FDA re­jects Bio­Marin’s he­mo­phil­ia A gene ther­a­py, de­mand­ing more da­ta on dura­bil­i­ty

5 years ago
R&D
FDA+

Sor­ren­to ousts CFO as long-run­ning Covid-19 dra­ma con­tin­ues

5 years ago
People
Coronavirus

Covid-19 roundup: Fau­ci, Collins in­ter­vene to stop FDA plas­ma au­tho­riza­tion, cit­ing weak da­ta; Roche, Re­gen­eron try ...

5 years ago
Deals
Coronavirus

An­oth­er blow to NASH, dis­ap­point­ing tri­al re­sults spell end for dark­horse play­er Al­bireo

5 years ago
R&D

J&J inks in­dus­try's lat­est bolt-on buy­out with $6.5B deal to ac­quire Mo­men­ta, beef­ing up its au­toim­mune pipeline

5 years ago
Deals

PDU­FA meet­ing airs in­dus­try's take on time­li­ness, qual­i­ty of FDA com­mu­ni­ca­tions

5 years ago
FDA+

FDA hands Gilead a stun­ning re­jec­tion for block­buster RA can­di­date fil­go­tinib, deal­ing CEO O’Day a ma­jor set­back

5 years ago
R&D
FDA+

My­lan wins ear­ly FDA OK of a Tec­fidera knock­off, and they're launch­ing with an eye to top­pling Bio­gen's block­buster ...

5 years ago
R&D
FDA+
First page Previous page 810811812813814815816 Next page Last page
A service from the Financial Times